Alzheon Inc.

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

AriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval

The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in

The requirement for Biogen, Inc. and Eisai Co., Ltd. to conduct a Phase IV clinical trial as a condition of Aduhelm’s accelerated approval raises the question of whether Alzheimer’s disease patien